Autolus Net Income From Continuing Ops from 2010 to 2026
| AUTL Stock | USD 1.43 0.03 2.05% |
Net Loss | First Reported 2016-09-30 | Previous Quarter -47.9 M | Current Value -79.1 M | Quarterly Volatility 21.4 M |
Check Autolus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Autolus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.8 M, Interest Expense of 6.8 M or Selling General Administrative of 122.1 M, as well as many indicators such as Price To Sales Ratio of 64.73, Dividend Yield of 0.0 or PTB Ratio of 1.53. Autolus financial statements analysis is a perfect complement when working with Autolus Therapeutics Valuation or Volatility modules.
Autolus | Net Income From Continuing Ops | Build AI portfolio with Autolus Stock |
Historical Net Income From Continuing Ops data for Autolus Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Autolus Therapeutics represents a compelling investment opportunity.
Latest Autolus Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Autolus Therapeutics over the last few years. It is Autolus Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Autolus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Autolus Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (96,576,735) | |
| Coefficient Of Variation | (74.12) | |
| Mean Deviation | 64,747,168 | |
| Median | (57,875,000) | |
| Standard Deviation | 71,584,590 | |
| Sample Variance | 5124.4T | |
| Range | 215.7M | |
| R-Value | (0.87) | |
| Mean Square Error | 1312.4T | |
| R-Squared | 0.76 | |
| Slope | (12,357,381) | |
| Total Sum of Squares | 81989.7T |
Autolus Net Income From Continuing Ops History
About Autolus Therapeutics Financial Statements
Autolus Therapeutics investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Autolus Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -198.6 M | -188.7 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Autolus Therapeutics Correlation against competitors. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Autolus Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Autolus Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Autolus Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Autolus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.